PP
CRDF icon

Paloma Partners’s Cardiff Oncology CRDF Stock Holding History

Paloma Partners’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-29,090
Closed -$64.6K – 1243
2024
Q2 		$64.6K Buy
+29,090
New +$110K ﹤0.01% 1125
2017
Q3 		– Sell
-1,146
Closed -$104K – 2137
2017
Q2 		$104K Buy
+1,146
New +$73.8K ﹤0.01% 2075
2014
Q4 		– Sell
-178
Closed -$59K – 1177
2014
Q3 		$59K Buy
+178
New +$53.3K ﹤0.01% 938

Other funds holding CRDF

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Paloma Partners's CRDF Position: Q3 2024 in Review

Paloma Partners sold out of Cardiff Oncology (CRDF) in Q3 2024, closing a stake of 29,090 shares — an estimated $64.6K sold.

Paloma Partners first reported a position in CRDF in Q3 2014 and held it in 3 quarters. The position peaked at $104K in Q2 2017. 83 funds tracked by Wall St. Rank hold CRDF as of Q3 2024.

  • Paloma Partners reported no remaining Cardiff Oncology position as of Q3 2024 after selling out during the quarter.
  • Paloma Partners sold 29,090 Cardiff Oncology shares in Q3 2024, an estimated $64.6K.
  • Paloma Partners first reported a position in Cardiff Oncology in Q3 2014 and held it in 3 quarters.
  • Paloma Partners's Cardiff Oncology position peaked at $104K in Q2 2017.
  • 83 funds tracked by Wall St. Rank held Cardiff Oncology as of Q3 2024.

Based on Paloma Partners's 13F filing for Q3 2024, filed 14 Nov 2024.